APA (7th ed.) Citation

TE, K., L, B., A, S., M, Q., & GA, Y. (2025). Why are Higher CD34+ Cell Doses Associated with Improved Outcomes among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors - But Not for High-Risk Neuroblastoma? Pediatric hematology and oncology, 42(1), 63. https://doi.org/10.1080/08880018.2024.2420924

Chicago Style (17th ed.) Citation

TE, Knight, Broglie L, Sharma A, Qayed M, and Yanik GA. "Why Are Higher CD34+ Cell Doses Associated with Improved Outcomes Among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors - But Not for High-Risk Neuroblastoma?" Pediatric Hematology and Oncology 42, no. 1 (2025): 63. https://doi.org/10.1080/08880018.2024.2420924.

MLA (9th ed.) Citation

TE, Knight, et al. "Why Are Higher CD34+ Cell Doses Associated with Improved Outcomes Among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors - But Not for High-Risk Neuroblastoma?" Pediatric Hematology and Oncology, vol. 42, no. 1, 2025, p. 63, https://doi.org/10.1080/08880018.2024.2420924.